Progress on ABX464

Compound dampens intestinal inflammation by triggering IL-22 production in activated macrophages
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PARIS—ABIVAX, a biotechnology company targeting the immune system to eliminate viral diseases, recently announced the publication of a paper on its lead product candidate ABX464 in the July 7, 2017, online edition of Nature Scientific Reports. The paper, titled “The Anti-HIV Candidate ABX464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages” and authored by Prof. Jamal Tazi, et al., summarizes the experiments that explored the mechanisms by which ABX464 exerts its anti-inflammatory properties, as well as implications for potential therapeutic use in inflammatory bowel disease (IBD).
 
The new publication summarizes the in-vitro and in-vivo findings with ABX464 on reducing inflammation, as well as potential therapeutic implications. ABX464 was shown to stimulate the expression of the anti-inflammatory cytokine IL-22 in macrophages in preclinical testing.
 
In addition, ABX464 was shown to protect mice from the lethal effects of dextran sulfate sodium (DSS), which is an established animal model for experimental colitis. ABX464 treatment was not only critical for the survival of DSS-challenged mice, but also fully protected the histological structure of the murine intestine against changes induced by severe inflammation.
 
RNA profiling analysis showed that ABX464 induced the expression of IL-22, and this was demonstrated both in DSS-challenged mice as well as in in-vitro studies of LPS-stimulated bone marrow-derived macrophages. IL-22 is a cytokine that regulates tissue repair and recovery. The protective effect of ABX464 in these mice was substantially reduced by the simultaneous administration of antibodies to IL-22. ABX464 also showed a long-term protection against prolonged DSS-exposure after drug cessation. Furthermore, ABX464 reduced the colonic production of the pro-inflammatory cytokines IL-6 and TNFα and also the chemoattractant MCP-1.
 
“The results presented in this paper show for the first time that ABX464 specifically acts on the immune system to attenuate mucosal disease induced by DSS”, said Dr. Jamal Tazi, inventor of ABX464 and senior author of the paper. “ABX464’s ability to dampen intestinal inflammation in DSS-mice was clearly demonstrated. Additionally, its ability to reduce the inflammatory cytokines IL-6 and TNFα and induce the expression of IL-22 leading to tissue repair, and show long-lasting protective effects, is very promising.”

Related Topics

Published In

Volume 13 - Issue 9 | September 2017

September 2017

September 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue